Medtronic LABS: Opening Up Software To Expand Access to Healthcare

Medtronic

Medtronic LABS makes its digital health platform open source

Medtronic LABS accelerates access to healthcare in underserved communities around the world through technology. And now, the code behind its digital health platform SPICE is open source - making it available to anyone.

Since Medtronic LABS launched in 2013, the independent nonprofit with Medtronic funding has enrolled over 217,000 people in one million patients healthcare and trained over 8,000 community health workers in Kenya, Tanzania, Rwanda, Ghana, Sierra Leone, Bangladesh, Bhutan, and the United States.

SPICE is a digital health platform embedded directly within health systems and government digital ecosystems. Making its code available to health system partners and governments is just one way LABS approaches global health collaboratively.

And it's that spirit of collaboration that accelerates access in low-and middle-income communities.

How it works

At any given moment, community health workers are visiting patients in their homes and at community events, often in hard-to-reach places. Equipped with screening tools and SPICE, they screen patients for a range of conditions including hypertension, diabetes, malaria, and TB.

If needed, they refer patients to the nearest health facility where they are immediately connected to care. Medical staff confirm the diagnosis, and enroll the patient in LABS' programs, where they receive a personalized care plan.

The community health worker continues to follow up with patients directly based on their care plan.

This approach - pairing health tech with strong partnerships and community care - is working. LABS has screened half a million people for non-communicable diseases since 2014.

And open-source technology means more organizations, health systems, and governments can access LABS' health tech - connecting even more people to care.

"We offer a fundamentally new take on risk-based, data-driven community health, and we hope that by open sourcing our platform, our approach might be widely adopted," said LABS' Chief Strategy and Product Officer, Anne Stake.

Becoming open source also allowed LABS to receive the designation as a Digital Public Good by a multi-stakeholder United Nations-endorsed initiative that works to reduce barriers to the digitization of health systems.

"We made SPICE open source and applied to be a Digital Public Good to enable any health system innovator to use the technology and ultimately improve population health outcomes," said Stake.

Learn more about how Medtronic LABS is reimagining healthcare for communities around the world.

View additional multimedia and more ESG storytelling from Medtronic on 3blmedia.com.

Contact Info:
Spokesperson: Medtronic
Website: https://www.3blmedia.com/profiles/medtronic
Email: info@3blmedia.com

SOURCE: Medtronic



View source version on accesswire.com:
https://www.accesswire.com/810825/medtronic-labs-opening-up-software-to-expand-access-to-healthcare

News Provided by ACCESSWIRE via QuoteMedia

MDT
The Conversation (0)

PrairieSky Announces Fourth Quarter And Year-End Results For 2023, Including Record Oil Royalty Production, Strong Leasing Activity And Increased Annual Dividend

PrairieSky Royalty Ltd. (" PrairieSky " or the " Company ") (TSX: PSK) is pleased to announce its fourth quarter (" Q4 2023 ") and year-end operating and financial results for the period ended December 31, 2023. PrairieSky is also pleased to announce a 4% increase in its annual dividend to $1.00 per common share ($0.25 per common share quarterly).

Fourth Quarter Highlights

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

PrairieSky Announces 2023 Third Quarter Results

PrairieSky Royalty Ltd. (" PrairieSky " or the " Company ") (TSX: PSK) is pleased to announce its third quarter (" Q3 2023 ") results for the three-month period ended September 30, 2023.

Third Quarter Highlights

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
doctor with hands together, palms up below digital medical symbols

Innovations and Opportunities in European Healthcare Technologies

In recent years, European companies have emerged as trailblazers in healthcare technology, effectively changing the face of health and patient care. Through innovation, they're not only improving systems, processes and patient outcomes but also saving lives.

These advanced European technologies are often only distributed and implemented exclusively within the European Union. The good news is that it doesn't need to stay this way.

Bringing European healthcare technologies to the North American market can potentially improve healthcare in this part of the world, open up new market opportunities for investors and expose those companies to significant growth capital.

Keep reading...Show less

PrairieSky Announces 2023 Second Quarter Results, Including Record Oil Royalty Production

PrairieSky Royalty Ltd. (" PrairieSky " or the " Company ") (TSX: PSK) is pleased to announce its second quarter (" Q2 2023 ") results for the three-month period ended June 30, 2023.

Second Quarter Highlights:

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Nanalysis To Be Featured on Radius Research's Pitch, Deep Dive and Q&A Webinar

Webinar tomorrow Weds, June 21st at 2:00pm ET / 11AM MDT

Nanalysis Scientific Corp. ("the Company") (TSXV: NSCI) (OTCQX: NSCIF) (FRA: 1N1), a leader in portable NMR machines and MRI technology for industrial and research applications is pleased to invite investors and other interested parties to attend an upcoming interview with Market Radius Research. Martin Gagel of Market Radius Research and CEO Sean Krakiwsky and CFO Randall McRae are providing an update and outlook on Nanalysis' growth and opportunities.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Bausch Health Announces Fourth-Quarter and Full-Year 2023 Results

  • Fourth-Quarter revenues of $2.41 billion, up 10% on a Reported basis and up 4% on an Organic 1 basis
  • Full-Year revenues of $8.76 billion, up 8% on a Reported basis and 7% on an Organic 1 basis
  • Full-Year revenue growth in Salix, International, Solta and Bausch + Lomb segments on both a Reported and Organic 1 basis
  • GAAP Net Loss Attributable to Bausch Health Companies Inc. of $39 million for the quarter and $592 million for the year
  • Adjusted EBITDA Attributable to Bausch Health Companies Inc. 1 of $869 million for the quarter, up 6%, and $3.0 billion for the year, in line with prior year

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" the "Company," "we" or "our") today announced its fourth-quarter and full-year 2023 financial results

"I am pleased that we delivered against the financial guidance we established at the beginning of 2023. During the year, we made meaningful progress in driving performance across each of our business segments, continued to focus on our balance sheet and liquidity, and made significant progress on our key R&D initiatives, all helping to position the Company for continued growth and performance. We are excited about the positive momentum in our business as we enter 2024 and will continue to prioritize advancing our pipeline, investing in initiatives to continue to drive growth, and positioning the Company for long-term success," said Thomas J. Appio, Chief Executive Officer, Bausch Health.

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less

Knight Therapeutics Announces Regulatory Submission of Fostamatinib in Brazil

Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltda., has submitted a marketing authorization application to ANVISA, the Brazilian health regulatory agency, for fostamatinib for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. Knight has previously submitted marketing authorization applications for fostamatinib in Colombia and Mexico.

"This submission of fostamatinib demonstrates Knight's continued execution of our strategy of leveraging our solid platform and expertise to bring innovative therapies for important unmet healthcare needs in Latin America," said Samira Sakhia, President and Chief Executive Officer of Knight Therapeutics Inc.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Upfront Tuition Coverage Is a Game-Changer for Medtronic Employees

MAPS program helped remove barriers to education; Candi Sneed becomes first link in a chain of future engineers

Candi Sneed had always been passionate about pursuing higher education and a career in engineering. However, the cost of tuition and the lack of flexibility in traditional academic programs have been a barrier for her. That was until she discovered the Medtronic Advancement Pathways and Skill-building (MAPS) program

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less

Medtronic reports third quarter fiscal 2024 financial results

Delivers on commitments with strong growth in Core Spine, Cardiac Surgery, Structural Heart, Cardiac Pacing, and across many international markets; Diabetes increases double digits as U.S. business returns to growth; Raises full year guidance

Medtronic plc (NYSE:MDT) today announced financial results for its third quarter (Q3) of fiscal year 2024 (FY24), which ended January 26, 2024 .

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Medical Technology Stocks to Keep On The Radar

(NewsDirect)

The healthcare technology industry is one that offers investors a plethora of opportunities. With global healthcare spending soaring to approximately $8.3 trillion and nearly half of that amount allocated in the U.S. alone, the sector presents intriguing growth prospects. As the healthcare industry outpaces the overall global economy in growth, investors find themselves on the cusp of a promising market.

News Provided by TheNewsWire via QuoteMedia

Keep reading...Show less
Cleo Diagnostics

Making Earlier Detection of Ovarian Cancer a Reality

Corporate Presentation February 2024

Ovarian cancer diagnostics company, Cleo Diagnostics Limited (ASX:COV) (CLEO, or the Company) is bringing to market a simple blood test for the accurate and early diagnosis of ovarian cancer, using its novel patented CXCL10 biomarker.

Keep reading...Show less

Latest Press Releases

Related News

×